Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus
InterMune Submits CTA Amendment for ITMN-191 and Provides Update on Clinical Development Program
August 6th, 2007
InterMune, Inc. (NASDAQ:ITMN) and its partner Roche announced that on Monday, July 23rd, they submitted an amended Clinical Trial Authorization (CTA) with the relevant European regulatory authority, the final step before initiating a Phase 1b study of Hepatitis C Virus (HCV) protease inhibitor ITMN-191 in chronic hepatitis C patients. The CTA amendment takes into consideration new competitor information, preclinical and in-vitro data on ITMN-191 and pharmacokinetic observations from a Phase 1a study which was completed in May of 2007. InterMune also announced that it had earned a $10 million development milestone from Roche as part of the ongoing corporate collaboration....
Source: Hepatitis Weekly (2007-08-06)
|
